D001374Chemicals & DrugsD02.145.150D03.383.742.680.245.217D13.570.685.245.217D13.570.800.286.30021611390.62193AzacitidineFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonLeukemiaMD AndersonHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorELIAS JOSEPHJABBOURELIAS JOSEPH JABBOUR9124JABBOUR, ELIAS JOSEPHAssociate ProfessorNAVALDAVERNAVAL DAVER9643DAVER, NAVALAssistant ProfessorCOURTNEYDINARDOCOURTNEY DINARDO9868DINARDO, COURTNEYAssistant ProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessor74Professor10Assistant Professor14Associate Professor17.01230.00256151216research area of0.9804570.0146709353subject area for36428152Hasegawa K, Wei AH, Garcia-Manero G, Daver NG, Rajakumaraswamy N, Iqbal S, Chan RJ, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Sallman DAClinical lymphoma, myeloma & leukemiaAzacitidine Monotherapy in Patients With Treatment-Na?ve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2023 02; 23(2):127-137.Clin Lymphoma Myeloma Leuk2022-11-06T00:00:002022Azacitidine Monotherapy in Patients With Treatment-Na?ve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis.37087488Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O'Hayer K, Geschwindt R, Smith M, Zhou F, Naing ABritish journal of cancerPhase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. Br J Cancer. 2023 06; 128(12):2227-2235.Br J Cancer2023-04-22T00:00:002023Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.37276510Fenaux P, Gobbi M, Kropf PL, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian H, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein J, Gercheva-Kyuchukova L, Demeter J, Griffiths E, Yee K, D?hner K, Hao Y, Keer H, Azab M, D?hner HBlood advancesGuadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 2023 09 12; 7(17):5027-5037.Blood Adv2023-09-12T00:00:002023Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.37703506Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DAJournal of clinical oncology : official journal of the American Society of Clinical OncologyTolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904.J Clin Oncol2023-09-13T00:00:002023Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.38102772DiNardo CDAmerican journal of hematologyToward an improved understanding of hypomethylating agent and venetoclax therapies. Am J Hematol. 2024 Feb; 99(2):152-154.Am J Hematol2023-12-15T00:00:002023Toward an improved understanding of hypomethylating agent and venetoclax therapies.true1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professor